101 results
DEF 14C
ATXI
Avenue Therapeutics Inc
18 Mar 24
Information statement
4:59pm
with respect to the proposed reverse stock split and amendment to our articles of incorporation.
Certain United States Federal Income Tax Consequences … of the Reverse Stock Split
The following summary describes, as of the date hereof, certain material U.S. federal income tax consequences
PRE 14C
ATXI
Avenue Therapeutics Inc
8 Mar 24
Preliminary information
4:31pm
stock split and amendment to our articles of incorporation.
Certain United States Federal Income Tax Consequences of the Reverse Stock Split …
The following summary describes, as of the date hereof, certain material U.S. federal income tax consequences of the reverse stock split to holders of our
424B3
ATXI
Avenue Therapeutics Inc
2 Feb 24
Prospectus supplement
12:00am
CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS
PLAN OF DISTRIBUTION
LEGAL MATTERS
EXPERTS
WHERE YOU CAN FIND MORE INFORMATION
INCORPORATION … in effect at the time of any act or omission occurring prior to such amendment, alteration or repeal.
CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS
8-K
EX-4.2
8n3n2j
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.1
rg3jn6o py5s
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.2
vae1d7 elfq6kbcn9
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.1
vv0fn
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.4
nfpmlgadc36oprel1
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-10.2
zzk8wplsei0ch0q
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.3
zgmkg31oq1d41 fq
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
g70fpos6qvkb4kxsm
2 Nov 23
Prospectus supplement with pricing info
9:00am